期刊文献+

罗氟司特中有关物质的鉴定和含量测定 被引量:7

Identification and quantitative analysis of related substances in roflumilast
原文传递
导出
摘要 目的:建立以高效液相色谱法测定罗氟司特中有关物质含量,并对主要降解杂质进行结构确证。方法:采用C18色谱柱(125.0 mm×4.0 mm,5μm),以磷酸盐缓冲液和乙腈为流动相,梯度洗脱,流速1.0 mL·min-1,检测波长247 nm。结果:线性范围为10~180μg·mL-1(r=0.9999,n=7),定量限为0.24μg·mL-1,检测限为0.07μg·mL-1。确定了酸、碱及氧化条件下主要降解产物的结构。结论:该方法准确、可行,精密度高,可用于罗氟司特有关物质的鉴定和含量测定。 Objective: To establish an HPLC method for the quantitative determination of roflumilast in the presence of degradation products,and to identify the structures of main degradation impurities. Methods: A C18 (125 mm×4.0 mm,5 μm) column was adopted with a mobile phase of phosphate buffer and acetonitrile at the flow rate of 1.0 mL·min-1 and detected at 247 nm. Results: An excellent separation was achieved for roflumilast and its related substances. The LOQ and LOD were 0.24 μg·mL-1 and 0.07 μg·mL-1,respectively. A linear response (r=0.9999) was observed for samples ranging from 10 to 180 μg·mL-1. The structures of degradation products under acidity,alkaline and oxidative conditions were identified,too. Conclusion: The method is shown to be simple,precise,accurate and can be applied to the determination of roflumilast.
出处 《药物分析杂志》 CAS CSCD 北大核心 2013年第10期1726-1730,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 罗氟司特 有关物质 含量测定 降解杂质鉴定 高效液相色谱 roflumilast related substance assay identificalion of degradation impurity HPLC
  • 相关文献

参考文献12

  • 1Rabe KF,Hurd S,Anzueto A,et al.Global strategy for the diagnosis, management,and prevention of chronic obstructive pulminary disease: GOLD executive summary[J].Am Respir Crit Care Med,2007,176(6): 532. 被引量:1
  • 2McClay JL,Adkins DE,Isern NG,et al.1H Nuclear magnetic resonance metabolomics analysis identies novel urinary biomarkers for lung function[J].J Proteome Res,2010,9(6): 3083. 被引量:1
  • 3Lopez AD,Shibuya K,Rao C,et al.Chronic obstructive pulmonary disease: current burden and future projections[J].Eur Respir J,2006,27: 397. 被引量:1
  • 4National Heart,Lung,and Blood Institute.How Is COPD Treated? [EB/OL].[20120608].http://www.nhlbi.nih.gov/health/healthtopics/topics/copd/treatment.html. 被引量:1
  • 5Rabe KF.Update onroflumilast,a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease[J].Br J Pharmacol,2011,163(1): 53. 被引量:1
  • 6Amschler H.Fluoroalkoxysubstituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors [P].PCT Patent WO95/01338,19950112. 被引量:1
  • 7Kobayashi M,Kubo S,Iwata M, et al.ASP3258,an orally active potent phosphodiesterase 4 inhibitor with low emetic activity[J].Int Immunopharmacol,2011,11(6): 732. 被引量:1
  • 8Pinner NA,Hamilton LA,Hughes A.Roflumilast: a phosphodiesterase4 inhibitor for the treatment of severe chronic obstructive pulmonary disease[J].Clin Ther,2012,34(1): 56. 被引量:1
  • 9Barhate VD,Deosthalee P.Rapid liquid chromatographic method for the determination of roflumilast in the presence of degradation products[J].Indian J Pharm Sci,2010,72(3): 401. 被引量:1
  • 10Hatzelmann A,Schudt C.Antiinammatory and immunomodulatory potential of the novel PDE4 inhibitor roumilast in vitro[J]. J Pharmacol Exp Ther,2001,297: 267. 被引量:1

同被引文献45

  • 1孙曙光,张淑霞,王红霞,沈敬山,张树军.中药补骨脂化学成分及磷酸二酯酶Ⅴ抑制活性测定[J].理化检验(化学分册),2007,43(11):958-960. 被引量:4
  • 2BARHATE V D, DEOSTHAI.EE P. Rapid liquid chromatographic method for the determination of Roflumilast in the presence of degradation products in dian[J]. J Pharm Sci, 2010,72(3)..401-404. 被引量:1
  • 3THEVIS M, KRUG O, SCHANZER W. Monitoring phospho- diesterase-4 inhibitors using liquid chromatography/ (tandem) mass spectrometry in sports drug testing [ J ]. Rapid Commun Mass Spectrom, 2013,27 ( 4 ) : 993-1004. 被引量:1
  • 4KNEBEL N G, HERZOG R, REUTTER F, et al. Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2012,893- 894(1) :82-91. 被引量:1
  • 5THAPPALI S R,VARANASI K V,VEERARAGHAVAN S, et al. Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC- MS/MS :application for a pharmacokinetic study[ J] .J Mass Spectrom,2012,47(12) : 1612-1619. 被引量:1
  • 6BETHKE T D, BOHMER G M, HERMANN R, et al.Dose- proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor [ J ]. Clin Pharmacol, 2007,47 (1) :26-36. 被引量:1
  • 7FDA. Center for drug evaluation and research [ EB/OL ]. [ 2010 - 08 - 31 ]./http://www. accessdata, fda. gov! drugsatfda docs/nda/2011/022522rig/022522rigls000- PharmR.pdf. 被引量:1
  • 8BOLAND S,ALEN J,BOURIN A,et al.Novel Roflumilast analogs as soft PDE4 inhibitors[J].Bioorg Med Chem Lett,2014,24(18):4594. 被引量:1
  • 9MILARA J,MORELL A,BALLESTER B,et al.Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist[J].Respir Res,2015, 16(1):12. 被引量:1
  • 10HAN S,KARLOWICZ-BODALSKA K,POTACZEK P,et al. Identification of unknown impurity of azelaic acid in liposomal formulation assessed by HPLC-ELSD,GC-FID,and GC-MS[J]. AAPS Pharm Sci Tech,2014,15(1):111. 被引量:1

引证文献7

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部